West Oak Capital LLC Sells 50 Shares of Danaher Co. (NYSE:DHR)

West Oak Capital LLC reduced its stake in Danaher Co. (NYSE:DHR) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,411 shares of the conglomerate’s stock after selling 50 shares during the quarter. West Oak Capital LLC’s holdings in Danaher were worth $2,390,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DHR. Fort Pitt Capital Group LLC increased its holdings in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after buying an additional 7,421 shares during the last quarter. Good Life Advisors LLC bought a new stake in Danaher during the third quarter worth about $217,000. Harvest Portfolios Group Inc. increased its stake in Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after acquiring an additional 2,465 shares during the last quarter. ORG Partners LLC raised its holdings in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in shares of Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after acquiring an additional 11,216 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of NYSE DHR opened at $239.83 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm’s 50-day simple moving average is $235.52 and its 200 day simple moving average is $253.65. The stock has a market cap of $173.22 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business earned $2.02 EPS. The business’s revenue was up 3.1% on a year-over-year basis. As a group, research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DHR. Stephens reissued an “overweight” rating and set a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Finally, TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.